ASTRO: Shorter Radiation Feasible for Low-, Intermediate-Risk Prostate Cancer

MONDAY, Oct. 16, 2023 -- At five years, five-fraction stereotactic body radiotherapy (SBRT) is noninferior to control radiotherapy for biochemical/clinical failure (BCF) in men with localized prostate cancer (LPCa), according to a study presented at...